1. Home
  2. |Insights
  3. |Private Party MEO Teammate Allowed Intervention To Protect Proprietary Information

Private Party MEO Teammate Allowed Intervention To Protect Proprietary Information

Client Alert | 1 min read | 12.14.06

In the protest of a contract award to the Government's Most Efficient Organization (MEO) in an A-76 public/private procurement, the COFC granted MEO private team member Lockheed Martin Services, Inc.'s motion to intervene as a matter of right for the limited purpose of protecting its trade secrets and proprietary data (Northrop Grumman Information Technology, Inc. v. United States). The MEO did not have legal representation separate from the awarding agency, and the COFC concluded that Lockheed's interests were not adequately represented by agency counsel in the context of an A-76 procurement in which agency counsel must "wear multiple hats at the same time" and where agency counsel admitted that the "most comfortable" hat is representing the Source Selection Authority.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights